Interleukin-6 in cardiac surgery

Yuan, Shi‐Min; Lin, Hao

doi:10.18054/pb.v119i2.4928

Cited by 5 publications

(4 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It was therefore proposed that, in these conditions, elevation of IL-6 was probably the results of the inflammatory process in relation to anesthesia, surgical trauma, cardiopulmonary bypass and perioperative complications. Besides, mutations, environmental changes and acquired adjustment of transforming growth factor (TGF)-β superfamilyrelated genes may explain at least partly the mechanisms of congenital PAH [12][13][14]. In these studies, it was revealed that an imbalance of vascular cellular proliferation, driven by stimulation of excessive growth factors, such as TGF-β family signaling, platelet derived growth factor (PDGF) and Notch receptor play an important role in the development of PAH [15].…”

Section: Introductionmentioning

confidence: 99%

Interleukin-13 in the pathogenesis of pulmonary artery hypertension

Yuan

2019

Journal of Laboratory Medicine

Self Cite

View full text Add to dashboard Cite

Background Interleukin (IL)-13 is a regulatory factor of tissue remodeling and is involved in the pathogenesis of pulmonary artery hypertension (PAH). However, the implications of IL-13 in PAH remains uncertain. This article aims to describe the current knowledge on production and function of IL-13 and its receptors in the mechanisms of PAH. Content The study materials of this article were based on comprehensive literature retrieval of publications of IL-13 in PAH. These study materials were carefully reviewed, analyzed and discussed. Summary IL-13 levels in blood and lung tissue were elevated in both animal models of PAH and patients with PAH in comparison to non-PAH controls. Types I and II IL-13 receptors participate in pulmonary artery remodeling through signal transducer and activator of transcription (STAT)6 or through phosphatidylinositol 3-kinase (PI3K), STAT3 and mitogen activated protein kinase (MAPK) pathways. Oxidant, arginase 2 (Arg2) and hypoxia-inducible factor 1α are involved in the proliferation of pulmonary artery smooth muscle cells. Outlook Types I and II IL-13 receptors play an important role in the IL-13 signaling by STAT6 via Janus kinase kinases, and by PI3K, STAT3 and MAPK pathways, respectively. Alternative pathways, including oxidant, Arg2 and hypoxia-inducible factor 1α might be also involved in the pathological process of PAH development. Investigational therapies by inflammatory suppression or thrombolytic and anticoagulant agents could inhibit intimal hyperplasia of the pulmonary arteries and suppress pulmonary vasculature remodeling. Drug research and development oriented by this hypothesis would confer benefits to the treatment of PAH.

show abstract

Section: Introductionmentioning

confidence: 99%

Interleukin-13 in the pathogenesis of pulmonary artery hypertension

Yuan

2019

Journal of Laboratory Medicine

Self Cite

View full text Add to dashboard Cite

show abstract

“…Our finding of comparable levels of IL-6 early after MiECC and CECC is consistent with the findings of other studies [ 9 , 25 ]. In the study by Fromes et al [ 1 ], the pro-inflammatory cytokine IL-6, which also has been reported to be a reliable biomarker of cardiac dysfunction and myocardial damage [ 26 ], was significantly lower in the early postoperative stages after MiECC compared with CECC. A possible explanation for the lack of difference between the groups in the current study could be the effect of the volatile anaesthetic agent sevoflurane on the immune response.…”

Section: Discussionmentioning

confidence: 99%

Impact of minimal invasive extracorporeal circulation on systemic inflammatory response – a randomized trial

Halle,

Benhassen,

Søberg

et al. 2024

J Cardiothorac Surg

View full text Add to dashboard Cite

Background Extracorporeal circulation causes a systemic inflammatory response, that may cause postoperative haemodynamic instability and end-organ dysfunction. This study aimed to investigate the impact of minimal invasive extracorporeal circulation (MiECC) on the systemic inflammatory response compared with conventional extracorporeal circulation (CECC). Methods Patients undergoing coronary artery bypass grafting were randomized to MiECC (n = 30) and CECC (n = 30). Primary endpoint was tumor necrosis factor-α. Secondary endpoints were other biochemical markers of inflammation (IL1β, IL6 and IL8, C-reactive protein, leukocytes), and markers of inadequate tissue perfusion and tissue damage (lactate dehydrogenase, lactate and creatine kinase-MB). In addition, we registered signs of systemic inflammatory response syndrome, haemodynamic instability, atrial fibrillation, respiratory dysfunction, and infection. Results Patients treated with MiECC showed significantly lower levels of tumor necrosis factor-α than CECC during and early after extracorporeal circulation (median: MiECC 3.4 pg/mL; CI 2.2–4.5 vs. CECC 4.6 pg/mL; CI 3.4–5.6; p = 0.01). Lower levels of creatine kinase-MB and lactate dehydrogenase suggested less tissue damage. However, we detected no other significant differences in any other markers of inflammation, tissue damage or in any of the clinical outcomes. Conclusions Lower levels of TNF-α after MiECC compared with CECC may reflect reduced inflammatory response, although other biochemical markers of inflammation were comparable. Our results suggest better end-organ protection with MiECC compared with CECC. Clinical parameters related to systemic inflammatory response were comparable in this study. Clinical registration number NCT03216720.

show abstract

“…The interleukin (IL) family is a group of cytokines involved in the pathogenesis of inflammatory, allergic, infectious, immunodeficient, neoplastic, fibrotic, and hypoxic disorders [1,2] . Of the cardiac surgical patients, those with aortic dissection (AD) showed particular inherent relationships to IL-6 [3] . Clinical research revealed, in patients receiving an aortic aneurysm/dissection repair, that the circulating IL-6 levels differed between acute AD and hypertensive or healthy controls [3] .…”

Section: Introductionmentioning

confidence: 99%

“…Of the cardiac surgical patients, those with aortic dissection (AD) showed particular inherent relationships to IL-6 [3] . Clinical research revealed, in patients receiving an aortic aneurysm/dissection repair, that the circulating IL-6 levels differed between acute AD and hypertensive or healthy controls [3] . However, there has been no report comprehensively describing the profiles of circulating IL-6 levels in patients with AD so far.…”

Section: Introductionmentioning

confidence: 99%

Profiles and Predictive Values of Interleukin-6 in Aortic Dissection: a Review

Yuan¹

2019

Braz J Cardiovasc Surg

Self Cite

View full text Add to dashboard Cite

Aortic dissection (AD) has been recognized to be associated with an inflammatory process. Clinical observations demonstrated that patients with AD had an elevated interleukin (IL)-6 level in comparison to hypertensive or healthy controls. Adverse events such as acute lung injury, postimplantation syndrome, and death are associated with an elevated IL-6 level. Thus, circulating IL-6 could be a reliable biomarker for the diagnosis of AD and for the eveluation of the therapeutic outcomes and the prognosis of AD patients. Therapeutic interventions aiming at attenuating the inflammatory status by IL-6 neutralization could effectively decrease the IL-6 level and thus reverse the progression of the disorder of AD patient. Endovascular aortic repair can effectively control the inflammatory cytokines. Selective antegrade cerebral perfusion with deep hypothermic circulatory arrest during aortic arch replacement shows better neuroprotectve effect with an improved IL-6 level of the cerebrospinal fluid. These results facilitate the understanding of the etiology of AD and guide the directions for the treatment of acute AD in the future. More effective therapeutic agents developed based on the theories of IL-6 signaling involved in the mechasims of AD are anticipated.

show abstract

Interleukin-6 in cardiac surgery

Abstract: Background and Purpose: Interleukin (IL)-6 is a multi-functional proand anti-inflammatory cytokine, and it has been

Cited by 5 publications

References 15 publications

Interleukin-13 in the pathogenesis of pulmonary artery hypertension

Interleukin-13 in the pathogenesis of pulmonary artery hypertension

Impact of minimal invasive extracorporeal circulation on systemic inflammatory response – a randomized trial

Profiles and Predictive Values of Interleukin-6 in Aortic Dissection: a Review

Contact Info

Product

Resources

About